<DOC>
	<DOCNO>NCT00768339</DOCNO>
	<brief_summary>AEG35156 show early evidence activity patient advance indolent B-cell lymphoma Phase 1 trial merit evaluation disease . This trial design determine recommend dose AEG35156 patient relapse refractory chronic lymphocytic leukemia ( CLL ) indolent B-cell lymphoma .</brief_summary>
	<brief_title>A Phase 1-2 , Multicenter , Open-Label Study AEG35156 Patients With Relapsed Refractory Chronic Lymphocytic Leukemia Indolent B-Cell Lymphomas</brief_title>
	<detailed_description>Apoptotic induction cancer cell seek therapeutic goal . Most successful anticancer agent activate apoptosis pathway cancer treat . Apoptotic pathway cell appear converge single family enzyme , caspase , proteases dismantle cell orderly , non-inflammatory fashion , result cell death . The X-linked Inhibitor Apoptosis ( XIAP ) know cellular inhibitor caspase , expression thereby block principal mean apoptosis . A wide range evidence indicate cellular overexpression member IAP family fundamental mean many cancer cell evade death , even presence strong extrinsic ( death receptor-mediated ) intrinsic ( mitochondria-mediated ) apoptotic cue . The inhibition cellular XIAP activity , specifically cancer cell stress prim apoptosis chemotherapeutic agent , view powerful mean tip balance towards cell death . In particular , XIAP show overexpressed lymphoma . AEG35156 second generation antisense target XIAP mRNA low XIAP level apoptotic threshold cancer cell , enhance sensitivity intrinsic death chemotherapy . AEG35156 show early evidence activity patient advance indolent B-cell lymphoma Phase 1 trial merit evaluation disease .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>X-Linked Inhibitor Apoptosis Protein</mesh_term>
	<criteria>Patients histologically confirm diagnosis CLL per NCIWG criterion Patients histologically confirm diagnosis one follow indolent Bcell lymphoma : ( Follicular lymphoma ( FL ) ; Small lymphocytic lymphoma ( SLL ) ; Marginal zone lymphoma ; Lymphoplasmacytic lymphoma ) Relapsed refractory patient fail least 2 prior line therapy , one may high dose therapy autologous stem cell transplantation . Steroids alone use autoimmune phenomenon qualify prior therapy ECOG performance less equal 2 Life expectancy least 3 month Age great equal 18 year Signed , write IRBapproved informed consent A negative serum pregnancy test ( applicable ) Acceptable liver function : ( Bilirubin within normal limit ; AST ( SGOT ) ALT ( SGPT ) less equal 2.5 x ULN le equal 5 x ULN liver lymphomatous involvement ) Acceptable renal function : ( Serum creatinine within normal limit , OR calculate creatinine clearance great equal 60 mL/min/1.73 m2 patient creatinine level institutional normal ) Acceptable hematologic status : ( Granulocyte great equal 1000 cells/uL ; Platelet count great equal 50,000 /uL ) Acceptable coagulation status : ( PT within normal limit ; PTT within normal limit ) For woman childproducing potential , use effective contraceptive method study Prior radiotherapy local disease allow provided disease progression document , treatment complete least 4 week prior registration Uncontrolled autoimmune hemolysis and/or thrombocytopenia Richter 's transformation Histologic transformation Patients peripheral neuropathy Active progressive leptomeningeal disease include presence relate symptom need corticosteroid . A CT MRI scan head necessary patient history leptomeningeal disease document stability prior lesion Pregnant nursing woman . NOTE : Women childbearing potential must agree use adequate contraception ( sterile surgically sterile ; hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately Men unwilling use acceptable form birth control engage sexual contact woman child bear potential Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Known infection HIV , hepatitis B , hepatitis C Serious nonmalignant disease could compromise protocol objective opinion investigator and/or sponsor Patients currently receive investigational agent . Subjects use previous antisense oligonucleotide last 90 day exclude Unwillingness inability comply procedure require protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>antisense</keyword>
	<keyword>AEG35156</keyword>
	<keyword>lymphocytic</keyword>
	<keyword>lymphoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>B-cell</keyword>
</DOC>